Vancouver, British Columbia–(Newsfile Corp. – March 2, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMBDF) (FSE: 6UF) (“NeonMind“) is pleased to announce that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind’s preclinical trial. The provisional patent applications include data…


Previous articlePsychedelics Company Silo Wellness Inc. (Formerly Yukoterre Resources Inc.) Announces Successful Completion of Reverse Take-Over Transaction
Next articleNuminus and Syreon Provide Psilocybin Compassionate Access Trial Update